Evommune EVMN
NYSE EVMN
$8.31 -0.08 (-0.95%)
As of: Sep 29, 2026 · 3:59 PM EDT

Evommune (EVMN) EBITDA (2024 - 2026)

Updated

Evommune's EBITDA came in at -$34.34 million for Q2 2026, compared with -$22.62 million a year earlier.

Analysis

Evommune (EVMN) EBITDA (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Evommune reported EBITDA of -$100.36 million; for FY2025, it was -$79.68 million.

  • Going back by year, EBITDA was -$68.73 million in FY2024.
  • Business Quant data shows EVMN's EBITDA at -$23.61 million (Q1 2026), -$29.39 million (Q4 2025) and -$13.02 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 9.10 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 8.33 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 999.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 5.09 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 4.63 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -9.70 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 5.89 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 1.30 Bn
10 Evommune 304.40 Mn -333.11 Mn - -34.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -34.34 Mn
Mar 31, 2026 -23.61 Mn
Dec 31, 2025 -29.39 Mn
Sep 30, 2025 -13.02 Mn
Jun 30, 2025 -22.62 Mn
Mar 31, 2025 -14.66 Mn
Dec 31, 2024 -21.09 Mn
API Access

Evommune EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=EVMN&period=max&api_key=YOUR_API_KEY